The United Kingdom and the United States have announced a key bilateral deal that will preserve no duties on British pharmaceutical exports going into the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to increase expenditure on drugs through the National Health Service (NHS). This move guarantees that duties on these key goods will remain at zero for a timeframe of the next three years.
This development follows recent threats to significantly raise tariffs on branded drug imports, with increases floated up to one hundred percent.
"This agreement with the UK strengthens the global environment for cutting-edge drugs and brings much-needed fairness to transatlantic drug exports," a statement declared.
Economic Impact
Medicines are one of the Britain's most significant exports to the America, which is easily the biggest buyer for leading companies like GSK and AstraZeneca.
Statistics reveal that in the year leading up to September, the UK shipped drugs worth £11.1bn to the US. This amount accounted for nearly one-fifth of all goods exports in that timeframe.
"This deal protects work, stimulates capital expenditure and sets the stage for the UK to become a global hub for medical research," a government official commented.
Specific NHS Changes
The agreement includes several specific pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it deems new treatments to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to raise total NHS spending on medicines from 0.3 percent of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The percentage manufacturers must pay back to the NHS to prevent overspending will be restricted at 15%. Previously, refunds were more than 20%.
Broader Context
The pact comes amid a protracted tension between the drug companies and the UK government over drug pricing and approval rates.
These tensions were exacerbated by assertions that American customers were charged several times more for the equivalent treatments than consumers in the other developed nations.
Recently, several major drug company projects in the UK have been paused or abandoned, while multi-billion-dollar expansions have been announced toward American operations.
The Science Minister acknowledged that the NHS must invest a greater share on drugs, noting that its spending on drugs had decreased as a share of its overall budget over the last ten years.
